focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 22.00
Ask: 23.00
Change: -0.75 (-3.23%)
Spread: 1.00 (4.545%)
Open: 24.25
High: 24.50
Low: 22.50
Prev. Close: 23.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

Fri, 15th Jul 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Ncondezi Energy Ltd, up 91% at 1.48 pence, 12-month range 0.004p-1.90p. The Mozambique-based power developer says it has launched a feasibility study for a 300 megawatt solar photovoltaic power plant and battery energy storage system. The study will require four months to be completed and will be funded through available capital after completing the restructuring of the Seritza term loan. The solar project will be located within the Ncondezi concession area, with three sites identified, and have an estimated pre-money net present value between USD60 million and USD65 million.

----------

N4 Pharma PLC, up 21% at 2.85 pence, 12-month range 2.02p-10.43p. In a pre-clinical study of delivery system Nuvec with TNF-alpha, known as Medicines Discovery Catapult, there is clear tumour suppression with 10 micrograms of TNF-alpha loaded into Nuvec, a lower dose than used in earlier studies. Biochemical analysis of blood and tissue samples show that treatment led to an increase in circulating plasma TNF-alpha levels. "We continue to make good progress in understanding how Nuvec can be used in the oncology space," says CEO Nigel Theobald.

----------

Novacyt SA, up 8.5% at 116.99 pence, 12-month range 1.06p-123.77p. The clinical diagnostics firm says its 'exsig' Covid-19 direct real-time PCR test has been approved in the UK under the the UK Health Security Agency's coronavirus test device approvals regulations. The test "removes the need for manual or automated extraction solutions to significantly improve laboratory workflow and reduce costs".

----------

DP Poland Ltd, up 6.9% at 6.20 pence, 12-month range 5.00p-9.00p. The franchise in Poland for Domino's Pizza said system sales were significantly above pre-Covid levels in June. The company saw like-for-like system sales increased by 24% compared to a year ago and by 23% compared to June 2019. Total system sales were up by 21% compared to June 2021 and 15% compared to June 2019. In the first 10 days of July, LFL system sales increased by 33% on a year before.

----------

AIM - LOSERS

----------

Fevertree Drinks PLC, down 27% at 869.50p, 12-month range 804.50p-2,871.00p. In the first half of 2022, the premium tonic water maker posts revenue of GBP160.9 million, up 14% from GBP141.8 million year-on-year. UK sales rise 6% to GBP53.5 million and US sales increase 11% to GBP40.1 million, while total Europe revenue jumps 27% to GBP52.4 million. However, Fevertree now expects earnings before interest, tax, depreciation and amortisation in a range of GBP37.5 million to GBP45 million, down from a prior range of GBP63 million to GBP66 million. In 2021, the company achieved Ebitda of GBP63.0 million. The company flags labour shortages in the US, resulting in greater UK production, which means greater exposure to increasing sea freight rates. In addition, glass availability has become "severely restricted" and industry-wide cost pressures, such as glass, have increased.

----------

Angle PLC, down 12% at 82.20 pence, 12-month range 71.70p-163.75p. The Surrey, England-based medical diagnostics company raises GBP20.1 million through the issue of 25.2 million shares via a placing, retail offer and subscription at a price of 80 pence per share, reflecting a 14% discount to Thursday's closing price at 93.50p. Net proceeds will be used to help its commercialisation plans for its Parsortix system. Now has 260.5 million shares issued overall.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Feb 2020 14:09

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Read more
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more
17 Feb 2020 15:25

Angle upbeat on German research into 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Monday that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of 'Parsortix' in multiple metastatic cancer types, with the main emphasis on metastatic breast cancer.

Read more
11 Feb 2020 10:51

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival

Read more
11 Feb 2020 07:41

Angle upbeat on research into Parsortix with melanoma patients

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.

Read more
30 Jan 2020 11:41

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance

Read more
23 Jan 2020 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
22 Jan 2020 11:00

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter

Read more
7 Nov 2019 13:50

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma

Read more
31 Oct 2019 15:38

Angle Submits Positive Test Results For Parsortix System To US FDA

Angle Submits Positive Test Results For Parsortix System To US FDA

Read more
4 Oct 2019 15:17

Angle upbeat on patent grant for prostate cancer blood assessment

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.

Read more
4 Oct 2019 08:58

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Angle Notes Queen Mary University's European Cancer Prognosis Patent

Read more
4 Sep 2019 14:09

Angle Reports Positive Study Results For Parsortix System

(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's liquid biopsy technology, meaning it

Read more
29 Aug 2019 10:57

Angle Ovarian Cancer Testing Platform Study Enrols First Patients

(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipated completion early in 2020.The study

Read more
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.